We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Abnormal Metabolite Observed in Early CKD Patients

By LabMedica International staff writers
Posted on 06 Aug 2019
Print article
Image: A histopathology of chronic interstitial nephritis in end-stage kidney disease. There is diffuse interstitial scarring with a nonspecific mononuclear infiltrate (Photo courtesy of Agnes B. Fogo MD, Michael Kashgarian MD).
Image: A histopathology of chronic interstitial nephritis in end-stage kidney disease. There is diffuse interstitial scarring with a nonspecific mononuclear infiltrate (Photo courtesy of Agnes B. Fogo MD, Michael Kashgarian MD).
Chronic kidney disease (CKD) has been a growing health burden worldwide, and the patients with CKD continue to suffer from a wide range of complication including electrolyte imbalance, fluid overload, bone and mineral metabolism disorder to anemia.

CKD has been recognized as risk factors for 25-hydroxyvitamin D (25(OH) D) deficiency and low levels of 25 (OH) D have been suggested to be a trigger factor of decreased level of hemoglobin. However, there is lack of information about the magnitude of 25(OH) D deficiency and hemoglobin level in Nepalese CKD patients.

Two Nepalese scientists associated with Purbanchal University (Kathmandu, Nepal) carried out a cross-sectional study was carried out between June 2016 to May 2017 in the patients visiting outpatient nephrology unit at Kathmandu medical and teaching hospital and a total 172 patients who met the inclusion criteria were included in the study. All the patients had had measurement of serum creatinine, 25(OH) D and urine albumin creatinine. Clinically stable and with a diagnosis of CKD stage 2–5 who were not on dialysis were recruited for the study.

The core variables of interest in this study were 25(OH) D level and hemoglobin concentration. The following covariates included in statistical analysis: age, sex, co-morbidities (hypertension, and diabetes), biochemical laboratory test including estimated glomerular filtration rate (eGFR), hemoglobin (Hb), intact parathyroid hormone (iPTH), serum phosphate, albumin, calcium, and phosphate. Electrochemiluminescence immunoassay (ECLIA) test was used to measure the level of 25(OH) D and cyanmethemoglobin method for the estimation of Hb level.

The scientists reported that the estimated prevalence of abnormal 25(OH) D metabolite of less than 30 ng/mL in the predialysis patients were (87.8%), with 32% and 55.8% deficiency and insufficiency 25(OH) D metabolite, respectively. On regression analysis, serum 25(OH) D was positively associated with male subjects, serum albumin, and eGFR, while inversely associated with age, iPTH. Hb concentration was found to be positively correlated with 25(OH) D in both univariate as well as in multivariate analysis.

The authors concluded that Hb concentration significantly, positively correlated with 25(OH) D age, eGFR and calcium level. Conversely, there was inverse relationship between Hb and iPTH. The study shows that lower level of 25(OH) D level are associated with lower level of Hb and higher level of iPTH, and could play a role in the development of anemia and hyperparathyroidism. The study was published on July 17, 2019, in the journal BMC Nephrology.

Related Links:
Purbanchal University

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.